Glenmark Pharmaceuticals has got the final approval from the US health regulator USFDA for sale of Tretinoin Capsules that are used in the treatment of leukemia.

The company has said in a BSE filing that “Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food & Drug Administration (USFDA) for Tretinoin Capsules, 10 mg.”

It added that the approved products is a generic version of Vesanoid Capsules, 10 mg, of Hoffmann La Roche, Inc. (which is no longer being marketed in the US).

Read EquityPandit’s Nifty Pharma Outlook for this week